Trial NCT02036502

View at ClinicalTrials.gov 
Org. Study IDs: 3475-023
Secondary IDs: 2013-003512-44 KEYNOTE-023 MK-3475-023

Last trial update was posted on 2021-04-08

MeSH Interventions

Dexamethasone Lenalidomide Pembrolizumab

MeSH Conditions

Multiple Myeloma Neoplasms, Plasma Cell

Other Conditions


Stopping Reasons

Business Reasons

Limitations And Caveats

Enrollment of participants into this study was stopped after the FDA implemented a clinical hold after determining the risks of pembrolizumab + pomalidomide or lenalidomide outweighed any potential benefit for participants with multiple myeloma.

Result Publications


Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID